# CVRx Q2 2026 revenue rises 16% to $15.7M but full-year guidance is cut to $58-60M

Canonical page: https://technooptimist.io/stories/cvrx-q2-2026-revenue-rises-16-to-15-7m-but-full-year-guidance-is-cut-to-2fd5d793
Date: 6 Aug 2026
About: [CVRx](https://technooptimist.io/companies/cvrx.md) · [Barostim](https://technooptimist.io/neurotech/barostim.md)
Original source: https://finviz.com/news/379271/cvrx-reports-second-quarter-2026-financial-and-operating-results

US revenue grew 21% to $14.8M while Europe fell 31% to $0.9M. CEO Kevin Hykes said the company was not satisfied with its lowered outlook. Humana's Medicare Advantage policy covering Barostim took effect on 1 May.

## Key facts

- US units 466 vs 391 a year earlier; active US centres 258 vs 240
- Gross margin 87%; net loss $14.0M; cash $64.6M
- Q3 revenue guided to $13.5-14.5M

---

The Techno Optimist tracks every frontier of technology, program by program: https://technooptimist.io/ (a Markdown version of any page: add .md to its URL; site map for agents: https://technooptimist.io/llms.txt).
Data API (JSON, realtime stream): https://technooptimist.io/developers. People read 5 pages free, then Reader $10/month; these Markdown pages are open to agents.